NCEP ATP III Cholesterol Guidelines and Updates

Anoop Agrawal, M.D.

Med-Peds Continuity Clinic Baylor College of Medicine

Background

Adult Treatment Panel of the National Cholesterol Education Program issued their third guideline for cholesterol management in 2001 - known as ATP III statin therapy have been published.

This has resulted in an addendum to ATP III published in July 2004.

Next update (ATP IV) expected in 2009.

.

Since publication, 5 major clinical trials of

Background cont. - The 5 studies:

Heart Protection Study - revealed 25% reduction in mortality regardless of baseline LDL levels ALLHAT - did not show statin benefit in those with HTN; result attributed to use of pravastatin as study drug PROVE IT - intensive statin therapy following acute coronary syndrome is superior PROSPER - demonstrated statin benefit even in the elderly ASCOT-LLA - LDL lowering with atorvastatin had considerable CVD risk reduction in those with multiple CVD risk factors. (in contrast to ALLHAT)

NCEP Major Risk Factors

Classification of an individual ’ s risk for cardiac events is based upon five risk factors: smoking hypertension low HDL (<40) family history age: 1st degree relative with MI <55yo for male, <65 yo for female male >45 yo, female >55 yo **HDL > 60: reduction of 1 risk factor

CVD Risk Assessment

Based upon the 10 year cardiovascular risk score.

>20% and/or coronary heart disease (CHD) equivalents: high risk very high risk : CHD + other risk factors 10-20% and 2+ risk factors: moderate high <10% and 2+ risk factors: moderate risk 0-1 risk factor: lower risk calculated using Framingham risk score

CHD Equivalents

What are the recognized Coronary Heart Disease equivalents?

Diabetes Mellitus Peripheral Arterial Disease Symptomatic Carotid Artery Disease (TIA or stroke of carotid origin) Abdominal Aortic Aneurysm 10 yr risk for CHD >20% with 2+ risk factors

Example of Framingham risk assessment calculator Found at www.nhlbi.nih.gov/gui delines/cholesterol can also google ’ 10 year cvd ’ and will be first hit

ATP III Guidelines 2004

Category LDL goal LDL level to begin TLC LDL level to begin statins High risk <100 mg/dl; optional <70 in very high risk ≥100 mg/dl 100 mg/dl Moderately high risk <130 mg/dl; optional <100mg/dl ≥130 mg/dl ≥ 130 mg/dl; 100 129 consider* Moderate risk <130 mg/dl ≥130 mg/dl ≥ 160 mg/dl Lower risk <160 mg/dl ≥160 mg/dl ≥ 190 mg/dl *for moderate high risk patients with 100-129 baseline or after TLC: initiation of LDL lowering drug to achieve LDL <100 mg/dl is an option Adapted from Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143; with modifications from Grundy, SM, Cleeman, JI, Merz, CN, et al, Circulation 2004; 110:227.

Case V.H.

V.H. is a 60 year old male with CAD, DM II, and tobacco use. His baseline lipid panel is: Cholesterol HDL LDL Triglycerides 210 40 148 180 What is your recommendation for managing his cholesterol?

A. TLC and simvastatin 20mg B. TLC and vytorin 10/40 C. TLC and atorvastatin 40mg D. TLC for 3 months, then reevaluate TLC: therapeutic lifestyle changes

Case V.H. cont...

Mr. V.H.

’ s 10 yr CVD risk places him at >20%. Having CAD and 2 additional risk factors promotes him to the very high risk group.

His LDL goal is <100 with the option to achieve LDL < 70 mg/dl In selecting a statin for high risk patients, intensity of therapy needs to achieve at least 40% reduction in LDL.

Remember not all statins are created equal.

2004 Addendum to ATP III

For High Risk : Prior to addendum: The treatment goal for high-risk patients was an LDL < 100. Drug therapy was initiated only if LDL ≥ 130.

UPDATE the goal at an : Overall goal is still an LDL < 100. There is a therapeutic option to set LDL < 70 for very high-risk patients Also initiate drug therapy if LDL ≥100; also have the option to add on if baseline already < 100.

Case M.H.

M.H. is a 48 yo female with uncontrolled HTN (today 160/80) and a smoker. Her FH is significant for her mother with heart disease at age 61. She currently is not on lipid therapy.

Her baseline lipid panel Total Chol LDL HDL Trigs 210 120 40 180 Which of the following do you recommend?

A. TLC only, she is at goal B. simvastatin 20mg C. omega-3 fatty acids D. ezetimibe 10mg

Case M.H. continued...

What is her classification and goal LDL?

Based on her 10 yr risk score (11%) she is Moderate High risk , goal LDL < 130. But <100 is therapeutic option if baseline is already <130 and has uncontrolled risk factors.

Simvastatin 20mg would be sufficient to reach goal.

Why not ezetimibe (Zetia)?

Not first-line choice. Recent study (ENHANCE) showed zetia did lower LDL, but did not show slowing or regression of atherosclerosis.

2004 Addendum to ATP III

In Moderate High Risk : Prior to addendum: < 130, and drug treatment was recommended if LDL is 130 or higher.

The treatment goal was an LDL UPDATE 100-129.

: The overall goal for moderately high risk patients is still an LDL < 130. There is a therapeutic option to set the treatment goal at an LDL < 100, and to use drug treatment if LDL is

2004 Addendum to ATP III

For both High and Moderate High: Prior to addendum: Guidelines did not explicitly emphasize achieving a certain percentage lowering of LDL cholesterol.

Update: Advises that the intensity of LDL lowering drug treatment in high-risk and moderately high-risk patients be sufficient to achieve at least a 30-40% reduction in LDL levels.

Comparison of the efficacy of statin drugs

Each doubling of the dose of a statin, gives only an additional 6% reduction of LDL from initial baseline at which statin was initiated.

Case 3: Myalgias due to statin

A 56 yo female is complaining about myalgias due to her therapy with simvastatin 40mg. Her LDL is 146. Her goal LDL is <100. Which of the following are viable options?

a. reduce simvastatin to 20mg nightly b. change to atorvastatin 40mg nightly c. change to niacin d. change to ezetimibe 10mg daily

Case 3 : Myalgias due to statin

a: Myalgias are dose dependent response to statins. Lowering the dose may prevent the symptoms. In this case, reducing the dose would not help reach goal b: Myalgias are not seen with every statin; no clear reason for this patient-variable response. If patient agreeable, then try another statin. Atorvastatin 40mg will be more effective than simvastatin 40mg at reaching goal.

c: Niacin does not help lower LDL.

d: Ezetimibe is a option if patient refuses to try another statin or has myalgias with another statin

Case 3: Myalgias due to Statin

Clinical Pearls: Frequency of statin-related myalgias with normal CK is approximately 10-20%.

Occurrence of myalgias is dose-related Ezetimibe can lower LDL by 20% Bile acid-resins are another alternative treatment option (colesevelam)

New FDA: Simvastatin

Data fro SEARCH trial incidence of adverse CV events was 25.7% in simvastatin 20mg group vs. 24.5% in 80 mg group Myopathy - 52 patients in 80-mg group vs. 1 in the 20mg group Rhabdo - 44

FDA: Simvastatin labeling

Simvastatin is more prone to drug interactions than other statins because it is extensively metabolism by or 20/40mg of rosuvastatin.

CYP3A4 Rates of rhabdomyolysis with simvastatin 80mg is higher than with 80mg atorvastatin

Summary

Recent updates affect patients in moderate high risk categories.

targeted to lower LDLs. high and Encourages more aggressive lipid control due to evidence of significant reduction in vascular events regardless of baseline level of LDL.

Some LDL goals are still optional. In general, patients with high and moderate high risk are

Summary

When initiating statin therapy, initial dose should target at least a 30-40% reduction in LDL.

If goal LDL requires more than a 50% reduction of baseline, then goal will likely be unattainable with current options.